RecruitingPhase 2Phase 3NCT07204275
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
Sponsor
Vertex Pharmaceuticals Incorporated
Enrollment
176 participants
Start Date
Sep 30, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria1
- Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility
Exclusion Criteria1
- Hypersensitivity to investigational medicinal product or to any of its excipients
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPovetacicept
Solution for Subcutaneous Injection.
DRUGTacrolimus
Capsules for Oral Administration.
Locations(86)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07204275
Related Trials
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
NCT056684036 locations
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT0709684345 locations
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT0696280091 locations
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT0715778740 locations
Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy
NCT065734111 location